AZA did not potentiate Ara-C-dependent cytotoxicity in RUNX1 wild-type OCI-AML2 cells, but significantly reduced the viability of AML cells bearing mutant RUNX1, OCI-AML5, and MonoMac1 (Figure 2D). The gene discussed is RUNX1; the disease is acute myeloid leukemia.